首页 > 最新文献

Cancer Management and Research最新文献

英文 中文
Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer. 全面分析乳腺癌基因 1 (BRCA-1) 在膀胱癌中的意义。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S467817
Xinyu Zhang, Xiaoxuan Tao, Yuxin Zhou, Guangyue Shi, Tianjiao Wang

Background: Bladder carcinoma (BLCA) is characterized by high morbidity, mortality, and treatment costs. Breast cancer gene 1 (BRCA1), a tumor suppressor gene, inhibits the development of malignant tumors. However, research on the significance of BRCA1 in BLCA is limited. This study aims to explore the importance of BRCA1 in BLCA using bioinformatic methods and immunohistochemistry.

Methods: Gene expression, clinical, and survival data were collected from the TCGA databases through the UCSC Xena platform (http://xena.ucsc.edu/). The TPM data from the TCGA and GETEx databases were integrated using the GEPIA database (http://GEPIA.cancer-pku.cn). The study then explored the differential expression, survival prognosis, functional enrichment, and immune cell infiltration analyses of BRCA1 in BLCA. A PPI network of BRCA1 was constructed using the STRING database, and a BRCA1-associated gene-gene interaction network was generated using the GeneMANIA database. Immunohistochemistry (IHC) assays were performed to verify the expression levels of BRCA1 in bladder tumour tissues and adjacent normal tissues.

Results: BRCA1 is associated with BLCA. Differential analysis indicated that BRCA1 acts as a risk factor for BLCA but does not show significant expression differences across genders, stages, tumor stages, lymph node stages, or metastasis stages. Additionally, staging was based on the eighth edition of the American Joint Committee on Cancer (AJCC) for BLCA. Co-expression network and Gene Set Enrichment Analysis (GESA) confirmed that BRCA1 is involved in various BLCA pathways. Furthermore, BRCA1 expression was also linked to immune cell infiltration. However, survival prognosis analysis revealed no significant correlation between the prognosis of BLCA and BRCA1.

Conclusion: We demonstrated that BRCA1 is a prospective predicted and immunological biomarker in BLCA, offering new avenues for potential therapies.

背景:膀胱癌(BLCA)的特点是发病率高、死亡率高、治疗费用高。乳腺癌基因 1(BRCA1)是一种肿瘤抑制基因,可抑制恶性肿瘤的发展。然而,有关 BRCA1 在 BLCA 中重要性的研究还很有限。本研究旨在利用生物信息学方法和免疫组化技术探讨 BRCA1 在 BLCA 中的重要性:方法:通过 UCSC Xena 平台(http://xena.ucsc.edu/)从 TCGA 数据库中收集基因表达、临床和生存数据。利用 GEPIA 数据库(http://GEPIA.cancer-pku.cn)整合了来自 TCGA 和 GETEx 数据库的 TPM 数据。研究随后探讨了 BLCA 中 BRCA1 的差异表达、生存预后、功能富集和免疫细胞浸润分析。利用 STRING 数据库构建了 BRCA1 的 PPI 网络,并利用 GeneMANIA 数据库生成了 BRCA1 相关基因-基因相互作用网络。免疫组化(IHC)检测验证了 BRCA1 在膀胱肿瘤组织和邻近正常组织中的表达水平:结果:BRCA1 与 BLCA 相关。差异分析表明,BRCA1 是膀胱癌的一个危险因素,但在不同性别、分期、肿瘤分期、淋巴结分期或转移分期中,BRCA1 的表达并无明显差异。此外,BLCA 的分期是根据美国癌症联合委员会(AJCC)第八版进行的。共表达网络和基因组富集分析(GESA)证实 BRCA1 参与了 BLCA 的各种通路。此外,BRCA1 的表达还与免疫细胞浸润有关。然而,生存预后分析表明,BLCA 的预后与 BRCA1 之间无明显相关性:我们证明了 BRCA1 是 BLCA 的前瞻性预测和免疫生物标志物,为潜在疗法提供了新途径。
{"title":"Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.","authors":"Xinyu Zhang, Xiaoxuan Tao, Yuxin Zhou, Guangyue Shi, Tianjiao Wang","doi":"10.2147/CMAR.S467817","DOIUrl":"10.2147/CMAR.S467817","url":null,"abstract":"<p><strong>Background: </strong>Bladder carcinoma (BLCA) is characterized by high morbidity, mortality, and treatment costs. Breast cancer gene 1 (BRCA1), a tumor suppressor gene, inhibits the development of malignant tumors. However, research on the significance of BRCA1 in BLCA is limited. This study aims to explore the importance of BRCA1 in BLCA using bioinformatic methods and immunohistochemistry.</p><p><strong>Methods: </strong>Gene expression, clinical, and survival data were collected from the TCGA databases through the UCSC Xena platform (http://xena.ucsc.edu/). The TPM data from the TCGA and GETEx databases were integrated using the GEPIA database (http://GEPIA.cancer-pku.cn). The study then explored the differential expression, survival prognosis, functional enrichment, and immune cell infiltration analyses of BRCA1 in BLCA. A PPI network of BRCA1 was constructed using the STRING database, and a BRCA1-associated gene-gene interaction network was generated using the GeneMANIA database. Immunohistochemistry (IHC) assays were performed to verify the expression levels of BRCA1 in bladder tumour tissues and adjacent normal tissues.</p><p><strong>Results: </strong>BRCA1 is associated with BLCA. Differential analysis indicated that BRCA1 acts as a risk factor for BLCA but does not show significant expression differences across genders, stages, tumor stages, lymph node stages, or metastasis stages. Additionally, staging was based on the eighth edition of the American Joint Committee on Cancer (AJCC) for BLCA. Co-expression network and Gene Set Enrichment Analysis (GESA) confirmed that BRCA1 is involved in various BLCA pathways. Furthermore, BRCA1 expression was also linked to immune cell infiltration. However, survival prognosis analysis revealed no significant correlation between the prognosis of BLCA and BRCA1.</p><p><strong>Conclusion: </strong>We demonstrated that BRCA1 is a prospective predicted and immunological biomarker in BLCA, offering new avenues for potential therapies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1305-1319"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy. 接受调强放射治疗的鼻咽癌患者炎症标志物的预后研究
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S481142
Linbo Tang, Xinjing Li, Yongbin Wang, Yuanhe Tong

Purpose: Inflammatory markers in the blood have been linked to tumor prognosis, but their specific prognostic significance in nasopharyngeal carcinoma (NPC) patients undergoing intensity-modulated radiotherapy (IMRT) is not well established. This study aims to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in this patient population.

Patients and methods: A total of 406 non-metastatic NPC patients were included in the study. NLR, PLR, and LMR were stratified according to their average values. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis was performed to evaluate the associations of NLR, PLR, and LMR with PFS and OS.

Results: Patients with NLR > 2.78 had worse PFS (P = 0.008) and OS (P < 0.001); PLR > 162.48 was related to lower PFS (P = 0.018) but not OS (P = 0.29); LMR > 5.05 showed no significant difference in PFS and OS compared to LMR ≤ 5.05 (P values were 0.13 and 0.94, respectively). Multivariate analysis indicated that NLR was an independent prognostic factor for PFS (HR, 1.674; 95% CI, 1.006-2.784; P = 0.047) and OS (HR, 4.143; 95% CI, 2.111-8.129; P = 0.000), while PLR and LMR did not demonstrate significant associations with PFS and OS.

Conclusion: This study identifies NLR as a novel and independent prognostic indicator for NPC patients receiving IMRT, offering valuable insights that could inform future clinical decision-making. In contrast, PLR and LMR did not demonstrate significant prognostic value in this context.

目的:血液中的炎症标志物与肿瘤预后有关,但它们在接受调强放射治疗(IMRT)的鼻咽癌(NPC)患者中的具体预后意义尚未明确。本研究旨在评估中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和淋巴细胞与单核细胞比值(LMR)在该患者群体中的预后价值:研究共纳入了 406 名非转移性鼻咽癌患者。根据 NLR、PLR 和 LMR 的平均值进行分层。采用 Kaplan-Meier 法估算无进展生存期(PFS)和总生存期(OS)。对NLR、PLR和LMR与PFS和OS的关系进行了Cox多变量回归分析:结果:NLR > 2.78的患者PFS(P = 0.008)和OS(P < 0.001)较差;PLR > 162.48与较低的PFS(P = 0.018)有关,但与OS(P = 0.29)无关;LMR > 5.05与LMR ≤ 5.05相比,PFS和OS无显著差异(P值分别为0.13和0.94)。多变量分析表明,NLR是PFS(HR,1.674;95% CI,1.006-2.784;P = 0.047)和OS(HR,4.143;95% CI,2.111-8.129;P = 0.000)的独立预后因素,而PLR和LMR与PFS和OS无明显关联:本研究发现,NLR是接受IMRT治疗的鼻咽癌患者的一个新的独立预后指标,为未来的临床决策提供了有价值的信息。相比之下,PLR 和 LMR 在这种情况下并未显示出显著的预后价值。
{"title":"Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy.","authors":"Linbo Tang, Xinjing Li, Yongbin Wang, Yuanhe Tong","doi":"10.2147/CMAR.S481142","DOIUrl":"10.2147/CMAR.S481142","url":null,"abstract":"<p><strong>Purpose: </strong>Inflammatory markers in the blood have been linked to tumor prognosis, but their specific prognostic significance in nasopharyngeal carcinoma (NPC) patients undergoing intensity-modulated radiotherapy (IMRT) is not well established. This study aims to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in this patient population.</p><p><strong>Patients and methods: </strong>A total of 406 non-metastatic NPC patients were included in the study. NLR, PLR, and LMR were stratified according to their average values. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis was performed to evaluate the associations of NLR, PLR, and LMR with PFS and OS.</p><p><strong>Results: </strong>Patients with NLR > 2.78 had worse PFS (P = 0.008) and OS (P < 0.001); PLR > 162.48 was related to lower PFS (P = 0.018) but not OS (P = 0.29); LMR > 5.05 showed no significant difference in PFS and OS compared to LMR ≤ 5.05 (P values were 0.13 and 0.94, respectively). Multivariate analysis indicated that NLR was an independent prognostic factor for PFS (HR, 1.674; 95% CI, 1.006-2.784; P = 0.047) and OS (HR, 4.143; 95% CI, 2.111-8.129; P = 0.000), while PLR and LMR did not demonstrate significant associations with PFS and OS.</p><p><strong>Conclusion: </strong>This study identifies NLR as a novel and independent prognostic indicator for NPC patients receiving IMRT, offering valuable insights that could inform future clinical decision-making. In contrast, PLR and LMR did not demonstrate significant prognostic value in this context.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1321-1328"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Sociodemographic Factors and Clinical Aspects on the Quality of Life of Surgically Treated Patients with Colorectal Cancer. 社会人口因素和临床因素对接受手术治疗的结直肠癌患者生活质量的影响
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-27 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S478179
Filip Świątkowski, Jakub Lambrinow, Tomasz Górnicki, Marta Jurga, Mariusz Chabowski

Introduction: Due to the increasing number of cases and the levels of mortality, colorectal cancer is still a major health problem. Therefore, the growing interest in the quality of life of patients and the assessment of the quality of life of patients with colorectal cancer seems to be particularly important. The aim of the study was to investigate and determine factors that have a significant impact on the QoL of patients who were diagnosed with colorectal cancer that was surgically treated in the Surgical Department of the 4th Military Clinical Hospital in Wroclaw.

Methods: 102 respondents were enrolled into the study. The QLQ-C30, QLQ-CR29 as well as an original questionnaire regarding the socioeconomic factors were used for the assessment. The information was supplemented with patients' clinical data.

Results: According to the QLQ-C30 questionnaire the average QoL of the respondents was 55%. Factors such as male gender, younger age, higher BMI, no significant weight loss, living with family, lower level of education and being professionally active have significant positive impact on QoL. In contrary, patients with more advanced and malignant cancer with tumor located in the right half of the colon had worse QoL. The particular domains of QoL influenced by these factors were also identified. Determining these factors will allow for more effective treatment, for the shortening of the hospitalization and finally for the reduction of the costs.

Conclusion: The better QoL of the patients with colorectal cancer treated surgically showed younger men, living with family and with the support from close people, professionally active, with primary level of education, and without significant weight loss, ie less than 5% of body weight in the last 6 months. Moreover, patients with cancer located in the left colon, at a lower stage, with a lower grading demonstrated a better QoL.

导言:由于患病人数和死亡率不断增加,大肠癌仍然是一个重大的健康问题。因此,人们对患者生活质量的关注与日俱增,对结直肠癌患者生活质量的评估显得尤为重要。本研究旨在调查并确定对弗罗茨瓦夫第四军事临床医院外科手术治疗的结直肠癌患者生活质量有重大影响的因素。评估使用了 QLQ-C30、QLQ-CR29 以及有关社会经济因素的原始问卷。患者的临床数据对这些信息进行了补充:根据 QLQ-C30 问卷,受访者的平均 QoL 为 55%。性别为男性、年龄较小、体重指数(BMI)较高、体重无明显减轻、与家人同住、教育程度较低和从事职业活动等因素对 QoL 有显著的积极影响。相反,肿瘤位于结肠右半部的晚期恶性肿瘤患者的 QoL 较差。此外,还确定了受这些因素影响的特定 QoL 领域。确定这些因素将有助于更有效的治疗,缩短住院时间,最终降低费用:通过手术治疗的结直肠癌患者的生活质量较好,这表明这些患者都是年轻男性,与家人生活在一起并得到亲朋好友的支持,从事职业活动,受过初等教育,体重没有明显下降,即在过去 6 个月中体重下降少于 5%。此外,癌症位于左侧结肠、分期较短、分级较低的患者的生活质量也较高。
{"title":"The Influence of Sociodemographic Factors and Clinical Aspects on the Quality of Life of Surgically Treated Patients with Colorectal Cancer.","authors":"Filip Świątkowski, Jakub Lambrinow, Tomasz Górnicki, Marta Jurga, Mariusz Chabowski","doi":"10.2147/CMAR.S478179","DOIUrl":"10.2147/CMAR.S478179","url":null,"abstract":"<p><strong>Introduction: </strong>Due to the increasing number of cases and the levels of mortality, colorectal cancer is still a major health problem. Therefore, the growing interest in the quality of life of patients and the assessment of the quality of life of patients with colorectal cancer seems to be particularly important. The aim of the study was to investigate and determine factors that have a significant impact on the QoL of patients who were diagnosed with colorectal cancer that was surgically treated in the Surgical Department of the 4th Military Clinical Hospital in Wroclaw.</p><p><strong>Methods: </strong>102 respondents were enrolled into the study. The QLQ-C30, QLQ-CR29 as well as an original questionnaire regarding the socioeconomic factors were used for the assessment. The information was supplemented with patients' clinical data.</p><p><strong>Results: </strong>According to the QLQ-C30 questionnaire the average QoL of the respondents was 55%. Factors such as male gender, younger age, higher BMI, no significant weight loss, living with family, lower level of education and being professionally active have significant positive impact on QoL. In contrary, patients with more advanced and malignant cancer with tumor located in the right half of the colon had worse QoL. The particular domains of QoL influenced by these factors were also identified. Determining these factors will allow for more effective treatment, for the shortening of the hospitalization and finally for the reduction of the costs.</p><p><strong>Conclusion: </strong>The better QoL of the patients with colorectal cancer treated surgically showed younger men, living with family and with the support from close people, professionally active, with primary level of education, and without significant weight loss, ie less than 5% of body weight in the last 6 months. Moreover, patients with cancer located in the left colon, at a lower stage, with a lower grading demonstrated a better QoL.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1293-1303"},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: a Case Report and Review of the Literature. 混合性髓样-乳头状甲状腺癌伴混合性淋巴结转移:病例报告与文献综述》(Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: A Case Report and Review of the Literature)。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-24 eCollection Date: 2024-01-01 DOI: 10.2147/CMAR.S464797
Yu Yang, Jingyi Zhang, Jianhua Wang

Papillary thyroid and medullary thyroid cancers are two distinct types of thyroid neoplasms. Co-occurrence of these cancers is rare, especially in mixed tumours with lymph node metastases. A 66-year-old man presented with a thyroid tumour. Thyroid ultrasonography revealed three separate nodules in the thyroid, suspected to be associated with lymph node metastasis. Although preoperative thyroid function was normal, calcitonin and carcinoembryonic antigen levels were elevated. The patient underwent a total cervical thyroidectomy with bilateral radical dissection. Histological and immunohistochemical analyses identified mixed medullary and papillary thyroid carcinoma (MMPTC) in the nodules in the left lobe of the thyroid and the isthmus. Mixed metastatic spread was observed in several lymph nodes from the neck dissection specimen. Accurate diagnosis of the rare co-occurrences of papillary and medullary thyroid carcinomas is crucial. TSH suppression can be effective for treating papillary thyroid carcinoma, whereas radical surgery is the preferred treatment for medullary thyroid carcinoma. Identifying lymph node metastasis before surgery is a key surgical strategy.

甲状腺乳头状癌和甲状腺髓样癌是两种不同类型的甲状腺肿瘤。这两种癌症很少同时发生,尤其是在有淋巴结转移的混合瘤中。一名 66 岁的男子患有甲状腺肿瘤。甲状腺超声检查发现甲状腺内有三个独立的结节,怀疑与淋巴结转移有关。虽然术前甲状腺功能正常,但降钙素和癌胚抗原水平升高。患者接受了颈部甲状腺全切除术和双侧根治性切除术。组织学和免疫组化分析发现,甲状腺左叶和甲状腺峡部的结节中存在髓样和乳头状混合型甲状腺癌(MMPTC)。在颈部切除标本的多个淋巴结中观察到混合转移扩散。准确诊断甲状腺乳头状癌和甲状腺髓样癌的罕见并发症至关重要。抑制促甲状腺激素可以有效治疗甲状腺乳头状癌,而根治性手术则是甲状腺髓样癌的首选治疗方法。手术前确定淋巴结转移是一项关键的手术策略。
{"title":"Mixed Medullary-Papillary Thyroid Carcinoma with Mixed Lymph Node Metastases: a Case Report and Review of the Literature.","authors":"Yu Yang, Jingyi Zhang, Jianhua Wang","doi":"10.2147/CMAR.S464797","DOIUrl":"https://doi.org/10.2147/CMAR.S464797","url":null,"abstract":"<p><p>Papillary thyroid and medullary thyroid cancers are two distinct types of thyroid neoplasms. Co-occurrence of these cancers is rare, especially in mixed tumours with lymph node metastases. A 66-year-old man presented with a thyroid tumour. Thyroid ultrasonography revealed three separate nodules in the thyroid, suspected to be associated with lymph node metastasis. Although preoperative thyroid function was normal, calcitonin and carcinoembryonic antigen levels were elevated. The patient underwent a total cervical thyroidectomy with bilateral radical dissection. Histological and immunohistochemical analyses identified mixed medullary and papillary thyroid carcinoma (MMPTC) in the nodules in the left lobe of the thyroid and the isthmus. Mixed metastatic spread was observed in several lymph nodes from the neck dissection specimen. Accurate diagnosis of the rare co-occurrences of papillary and medullary thyroid carcinomas is crucial. TSH suppression can be effective for treating papillary thyroid carcinoma, whereas radical surgery is the preferred treatment for medullary thyroid carcinoma. Identifying lymph node metastasis before surgery is a key surgical strategy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 ","pages":"1285-1291"},"PeriodicalIF":2.5,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends 在 mCRPC 治疗中整合 PARP 抑制剂:当前策略和新趋势
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-17 DOI: 10.2147/cmar.s411023
Bicky Thapa, Navonil De Sarkar, Subhajit Giri, Komal Sharma, Mingee Kim, Deepak Kilari
Abstract: Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy exhibited encouraging clinical outcomes in selected patients with mCRPC. More recently, three Phase III randomized clinical trials (RCTs) combining PARPi with androgen receptor signaling inhibitors (ARSIs) demonstrated improved antitumor activity compared to ARSI monotherapy in mCRPC patients as the first-line therapy. Clinical benefit was more pronounced in patients harboring DDR alterations, specifically BRCA1/2. Interestingly, antitumor activity was also observed irrespective of DDR gene mutations, highlighting BRCAness phenotype with androgen receptor blockade resulting in synergistic activity between ARSIs and PARPi. In this review, we discuss the clinical efficacy and safety data of the combination of PARPi plus ARSI in all Phase 3 randomized controlled trials (RCTs), emphasizing strategies for patient selection and highlighting emerging trends based on clinical trial data.

Keywords: PARP inhibitors, talazoparib, ARSI, DDR genes, HRD, metastatic CRPC
摘要:转移性耐阉割前列腺癌(mCRPC)预后不良。DNA损伤应答(DDR)基因在mCRPC中普遍发生改变,使其成为有希望的治疗靶点。聚(ADP 核糖)聚合酶抑制剂(PARPi)通过合成致死率,在 DDR 基因突变的 mCRPC 患者中显示出抗肿瘤活性。使用 PARPi 单药治疗的多项临床试验显示,在选定的 mCRPC 患者中取得了令人鼓舞的临床结果。最近,三项将PARPi与雄激素受体信号转导抑制剂(ARSI)联合应用的III期随机临床试验(RCT)显示,与单用ARSI作为一线疗法相比,PARPi在mCRPC患者中的抗肿瘤活性有所提高。临床获益在DDR改变(特别是BRCA1/2)患者中更为明显。有趣的是,无论 DDR 基因突变与否,都能观察到抗肿瘤活性,这凸显了 BRCAness 表型与雄激素受体阻断导致的 ARSIs 和 PARPi 之间的协同活性。在这篇综述中,我们讨论了所有3期随机对照试验(RCT)中PARPi联合ARSI的临床疗效和安全性数据,强调了患者选择策略,并根据临床试验数据突出了新趋势:PARP抑制剂、talazoparib、ARSI、DDR基因、HRD、转移性CRPC
{"title":"Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends","authors":"Bicky Thapa, Navonil De Sarkar, Subhajit Giri, Komal Sharma, Mingee Kim, Deepak Kilari","doi":"10.2147/cmar.s411023","DOIUrl":"https://doi.org/10.2147/cmar.s411023","url":null,"abstract":"<strong>Abstract:</strong> Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy exhibited encouraging clinical outcomes in selected patients with mCRPC. More recently, three Phase III randomized clinical trials (RCTs) combining PARPi with androgen receptor signaling inhibitors (ARSIs) demonstrated improved antitumor activity compared to ARSI monotherapy in mCRPC patients as the first-line therapy. Clinical benefit was more pronounced in patients harboring DDR alterations, specifically <em>BRCA1/2</em>. Interestingly, antitumor activity was also observed irrespective of DDR gene mutations, highlighting BRCAness phenotype with androgen receptor blockade resulting in synergistic activity between ARSIs and PARPi. In this review, we discuss the clinical efficacy and safety data of the combination of PARPi plus ARSI in all Phase 3 randomized controlled trials (RCTs), emphasizing strategies for patient selection and highlighting emerging trends based on clinical trial data.<br/><br/><strong>Keywords:</strong> PARP inhibitors, talazoparib, ARSI, DDR genes, HRD, metastatic CRPC<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"189 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine Learning-Based Predictive Model for Mortality in Female Breast Cancer Patients Considering Lifestyle Factors 考虑生活方式因素的基于机器学习的女性乳腺癌患者死亡率预测模型
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-14 DOI: 10.2147/cmar.s460811
Meixin Zhen, Haibing Chen, Qing Lu, Hui Li, Huang Yan, Ling Wang
Purpose: To construct a free and accurate breast cancer mortality prediction tool by incorporating lifestyle factors, aiming to assist healthcare professionals in making informed decisions.
Patients and Methods: In this retrospective study, we utilized a ten-year follow-up dataset of female breast cancer patients from a major Chinese hospital and included 1,390 female breast cancer patients with a 7% (96) mortality rate. We employed six machine learning algorithms (ridge regression, k-nearest neighbors, neural network, random forest, support vector machine, and extreme gradient boosting) to construct a mortality prediction model for breast cancer.
Results: This model incorporated significant lifestyle factors, such as postsurgery sexual activity, use of totally implantable venous access ports, and prosthetic breast wear, which were identified as independent protective factors. Meanwhile, ten-fold cross-validation demonstrated the superiority of the random forest model (average AUC = 0.918; 1-year AUC = 0.914, 2-year AUC = 0.867, 3-year AUC = 0.883). External validation further supported the model’s robustness (average AUC = 0.782; 1-year AUC = 0.809, 2-year AUC = 0.785, 3-year AUC = 0.893). Additionally, a free and user-friendly web tool was developed using the Shiny framework to facilitate easy access to the model.
Conclusion: Our breast cancer mortality prediction model is free and accurate, providing healthcare professionals with valuable information to support their clinical decisions and potentially promoting healthier lifestyles for breast cancer patients.

Keywords: breast cancer, machine learning, predict model, mortality, lifestyle, SHAP
目的:结合生活方式因素,构建一个免费、准确的乳腺癌死亡率预测工具,旨在帮助医护人员做出明智的决策:在这项回顾性研究中,我们使用了中国一家大型医院女性乳腺癌患者的十年随访数据集,共纳入 1,390 名女性乳腺癌患者,死亡率为 7%(96 人)。我们采用了六种机器学习算法(脊回归、k-近邻、神经网络、随机森林、支持向量机和极端梯度提升)来构建乳腺癌死亡率预测模型:结果:该模型纳入了重要的生活方式因素,如术后性活动、使用全植入式静脉通路端口和义乳佩戴,这些因素被确定为独立的保护因素。同时,十倍交叉验证证明了随机森林模型的优越性(平均 AUC = 0.918;1 年 AUC = 0.914,2 年 AUC = 0.867,3 年 AUC = 0.883)。外部验证进一步证明了模型的稳健性(平均 AUC = 0.782;1 年 AUC = 0.809,2 年 AUC = 0.785,3 年 AUC = 0.893)。此外,我们还利用 Shiny 框架开发了一个免费且用户友好的网络工具,以方便用户访问该模型:我们的乳腺癌死亡率预测模型免费且准确,可为医护人员提供有价值的信息以支持他们的临床决策,并有可能促进乳腺癌患者养成更健康的生活方式。 关键词:乳腺癌;机器学习;预测模型;死亡率;生活方式;SHAP
{"title":"Machine Learning-Based Predictive Model for Mortality in Female Breast Cancer Patients Considering Lifestyle Factors","authors":"Meixin Zhen, Haibing Chen, Qing Lu, Hui Li, Huang Yan, Ling Wang","doi":"10.2147/cmar.s460811","DOIUrl":"https://doi.org/10.2147/cmar.s460811","url":null,"abstract":"<strong>Purpose:</strong> To construct a free and accurate breast cancer mortality prediction tool by incorporating lifestyle factors, aiming to assist healthcare professionals in making informed decisions.<br/><strong>Patients and Methods:</strong> In this retrospective study, we utilized a ten-year follow-up dataset of female breast cancer patients from a major Chinese hospital and included 1,390 female breast cancer patients with a 7% (96) mortality rate. We employed six machine learning algorithms (ridge regression, k-nearest neighbors, neural network, random forest, support vector machine, and extreme gradient boosting) to construct a mortality prediction model for breast cancer.<br/><strong>Results:</strong> This model incorporated significant lifestyle factors, such as postsurgery sexual activity, use of totally implantable venous access ports, and prosthetic breast wear, which were identified as independent protective factors. Meanwhile, ten-fold cross-validation demonstrated the superiority of the random forest model (average AUC = 0.918; 1-year AUC = 0.914, 2-year AUC = 0.867, 3-year AUC = 0.883). External validation further supported the model’s robustness (average AUC = 0.782; 1-year AUC = 0.809, 2-year AUC = 0.785, 3-year AUC = 0.893). Additionally, a free and user-friendly web tool was developed using the Shiny framework to facilitate easy access to the model.<br/><strong>Conclusion:</strong> Our breast cancer mortality prediction model is free and accurate, providing healthcare professionals with valuable information to support their clinical decisions and potentially promoting healthier lifestyles for breast cancer patients.<br/><br/><strong>Keywords:</strong> breast cancer, machine learning, predict model, mortality, lifestyle, SHAP<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"110 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection 对于接受袖状切除术的非小细胞肺癌,新辅助化疗免疫疗法与化疗的安全性和有效性比较
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-11 DOI: 10.2147/cmar.s453924
Yanjun Qiu, Jinjiang Yu, Quanmin Guo, Jingyan Xu
Abstract: The prognosis of locally advanced non-small cell lung cancer (NSCLC) remains poor despite the addition of neoadjuvant chemotherapy, as it has been shown to improve 5-year absolute benefit survival by only 5%. Recently, neoadjuvant immunotherapy with immune checkpoint inhibitors (ICIs), combined with chemotherapy has shown promise in the treatment of locally advanced NSCLC. For NSCLC invading the main bronchus, sleeve resection has become the preferred modality to avoid pneumonectomy and reserve more cardiac or pulmonary function and to reduce postoperative morbidity and mortality. However, there has been a paucity of evidence to evaluate the safety and efficacy of neoadjuvant chemoimmunotherapy on bronchial-vascular reconstruction owing to the limited number of patients treated by sleeve lobectomy. Despite promising initial results, key knowledge gaps remain, including the impact on bronchial-vascular reconstruction, biomarkers predictive of ICI response, and the potential for specific perioperative complications associated with neoadjuvant chemoimmunotherapy in the context of sleeve resection. This review summarizes the latest literature evidence on the efficacy and safety of neoadjuvant chemoimmunotherapy approaches to address the unmet needs of sleeve resection of NSCLC treatment, describes the biomarkers predictive of ICI responses, and perioperative outcomes of sleeve resection after neoadjuvant chemoimmunotherapy.

Keywords: NSCLC, neoadjuvant chemotherapy, immune checkpoint inhibitors, sleeve lobectomy
摘要:尽管采用了新辅助化疗,但局部晚期非小细胞肺癌(NSCLC)的预后仍然很差,因为化疗仅能提高5年绝对生存率的5%。最近,免疫检查点抑制剂(ICIs)联合化疗的新辅助免疫疗法在治疗局部晚期非小细胞肺癌方面显示出了前景。对于侵犯主支气管的 NSCLC,袖状切除术已成为首选方式,以避免进行肺切除术,保留更多心肺功能,并降低术后发病率和死亡率。然而,由于采用袖状肺叶切除术治疗的患者人数有限,因此评估新辅助化疗免疫疗法对支气管-血管重建的安全性和有效性的证据还很少。尽管初步结果令人鼓舞,但仍存在一些关键的知识空白,包括对支气管-血管重建的影响、预测 ICI 反应的生物标志物,以及袖状切除术中新辅助化疗免疫疗法可能引起的特定围手术期并发症。本综述总结了新辅助化疗免疫治疗方法的疗效和安全性的最新文献证据,以满足NSCLC袖状切除治疗未满足的需求,描述了预测ICI反应的生物标志物以及新辅助化疗免疫治疗后袖状切除的围手术期结果:NSCLC、新辅助化疗、免疫检查点抑制剂、袖状切除术
{"title":"Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection","authors":"Yanjun Qiu, Jinjiang Yu, Quanmin Guo, Jingyan Xu","doi":"10.2147/cmar.s453924","DOIUrl":"https://doi.org/10.2147/cmar.s453924","url":null,"abstract":"<strong>Abstract:</strong> The prognosis of locally advanced non-small cell lung cancer (NSCLC) remains poor despite the addition of neoadjuvant chemotherapy, as it has been shown to improve 5-year absolute benefit survival by only 5%. Recently, neoadjuvant immunotherapy with immune checkpoint inhibitors (ICIs), combined with chemotherapy has shown promise in the treatment of locally advanced NSCLC. For NSCLC invading the main bronchus, sleeve resection has become the preferred modality to avoid pneumonectomy and reserve more cardiac or pulmonary function and to reduce postoperative morbidity and mortality. However, there has been a paucity of evidence to evaluate the safety and efficacy of neoadjuvant chemoimmunotherapy on bronchial-vascular reconstruction owing to the limited number of patients treated by sleeve lobectomy. Despite promising initial results, key knowledge gaps remain, including the impact on bronchial-vascular reconstruction, biomarkers predictive of ICI response, and the potential for specific perioperative complications associated with neoadjuvant chemoimmunotherapy in the context of sleeve resection. This review summarizes the latest literature evidence on the efficacy and safety of neoadjuvant chemoimmunotherapy approaches to address the unmet needs of sleeve resection of NSCLC treatment, describes the biomarkers predictive of ICI responses, and perioperative outcomes of sleeve resection after neoadjuvant chemoimmunotherapy.<br/><br/><strong>Keywords:</strong> NSCLC, neoadjuvant chemotherapy, immune checkpoint inhibitors, sleeve lobectomy<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"5 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound Diagnosis of Bilateral Primary Breast Burkitt Lymphoma in a 28-Year-Old Lactating Patient: A Case Report 超声诊断一名 28 岁哺乳期患者的双侧原发性乳腺伯基特淋巴瘤:病例报告
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-11 DOI: 10.2147/cmar.s483592
Qiu-Xia Jiang, Li-Jing Shi, Xiu-Yang Hong, Yu-Qin Zhu, Qiu-Ling Guo, Wen Xie, Guo-Rong Lyu
Abstract: Primary breast Burkitt lymphoma (PB-BL) is an exceedingly rare form of primary breast lymphoma. Ultrasonography is the preferred modality for diagnosing breast diseases; however, the ultrasonic features of Burkitt lymphoma have rarely been reported. Herein, we report a case of ultrasonically diagnosed bilateral PB-BL in a lactating patient and present a literature review. A 28-year-old female patient experienced bilateral breast engorgement starting more than a month after childbirth. At three months postpartum, the patient experienced extreme bilateral breast engorgement, with the skin appearing dark purple and jaundiced. Based on the imaging diagnosis, pathological, immunohistochemical, and molecular biological findings, she was diagnosed with Burkitt lymphoma involves bilateral breasts, right adrenal glands, uterus, and multiple bones. After 4 cycles of combination chemotherapy, the tumor basically disappeared, and then after autologous stem cell transplantation and one cycle of combination chemotherapy, the patient is generally in good condition and is under follow-up. We found that the ultrasonic characteristics of PB-BL are different from those of common breast cancer or lactation mastitis. PB-BL lesions are often multiple, large masses, and even involve the whole breast. The characteristic reticular structures are common in lesions, and irregular hyperechoic masses can be seen around it. The mass has abundant peripheral and internal blood flow signals, but internal calcification and attenuated posterior echoes of masses are rarely observed. Thus, the ultrasonic features of breast Burkitt lymphoma are somewhat specific and understanding these features is conducive to its early identification.

Keywords: Burkitt lymphoma, ultrasonography, case report
摘要:原发性乳腺伯基特淋巴瘤(PB-BL)是一种极为罕见的原发性乳腺淋巴瘤。超声波检查是诊断乳腺疾病的首选方法,但有关伯基特淋巴瘤超声波特征的报道却很少。在此,我们报告了一例哺乳期患者经超声诊断为双侧 PB-BL 的病例,并进行了文献综述。一名 28 岁的女性患者在产后一个多月开始出现双侧乳房胀痛。产后三个月时,患者双侧乳房极度胀痛,皮肤呈暗紫色并伴有黄疸。根据影像学诊断、病理学、免疫组化和分子生物学检查结果,她被诊断为伯基特淋巴瘤,累及双侧乳房、右侧肾上腺、子宫和多处骨骼。经过4个周期的联合化疗后,肿瘤基本消失,之后又进行了自体干细胞移植和一个周期的联合化疗,目前患者总体情况良好,正在随访中。我们发现,PB-BL 的超声特征不同于普通乳腺癌或哺乳期乳腺炎。PB-BL病变通常为多发性、大肿块,甚至累及整个乳房。病变中常见特征性网状结构,周围可见不规则高回声肿块。肿块周围和内部血流信号丰富,但很少观察到肿块内部钙化和衰减的后方回声。因此,乳腺伯基特淋巴瘤的超声波特征具有一定的特异性,了解这些特征有利于早期发现乳腺伯基特淋巴瘤:伯基特淋巴瘤 超声波检查 病例报告
{"title":"Ultrasound Diagnosis of Bilateral Primary Breast Burkitt Lymphoma in a 28-Year-Old Lactating Patient: A Case Report","authors":"Qiu-Xia Jiang, Li-Jing Shi, Xiu-Yang Hong, Yu-Qin Zhu, Qiu-Ling Guo, Wen Xie, Guo-Rong Lyu","doi":"10.2147/cmar.s483592","DOIUrl":"https://doi.org/10.2147/cmar.s483592","url":null,"abstract":"<strong>Abstract:</strong> Primary breast Burkitt lymphoma (PB-BL) is an exceedingly rare form of primary breast lymphoma. Ultrasonography is the preferred modality for diagnosing breast diseases; however, the ultrasonic features of Burkitt lymphoma have rarely been reported. Herein, we report a case of ultrasonically diagnosed bilateral PB-BL in a lactating patient and present a literature review. A 28-year-old female patient experienced bilateral breast engorgement starting more than a month after childbirth. At three months postpartum, the patient experienced extreme bilateral breast engorgement, with the skin appearing dark purple and jaundiced. Based on the imaging diagnosis, pathological, immunohistochemical, and molecular biological findings, she was diagnosed with Burkitt lymphoma involves bilateral breasts, right adrenal glands, uterus, and multiple bones. After 4 cycles of combination chemotherapy, the tumor basically disappeared, and then after autologous stem cell transplantation and one cycle of combination chemotherapy, the patient is generally in good condition and is under follow-up. We found that the ultrasonic characteristics of PB-BL are different from those of common breast cancer or lactation mastitis. PB-BL lesions are often multiple, large masses, and even involve the whole breast. The characteristic reticular structures are common in lesions, and irregular hyperechoic masses can be seen around it. The mass has abundant peripheral and internal blood flow signals, but internal calcification and attenuated posterior echoes of masses are rarely observed. Thus, the ultrasonic features of breast Burkitt lymphoma are somewhat specific and understanding these features is conducive to its early identification.<br/><br/><strong>Keywords:</strong> Burkitt lymphoma, ultrasonography, case report<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"55 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Green Dentistry in Oral Cancer Treatment Using Biosynthesis Superparamagnetic Iron Oxide Nanoparticles: A Systematic Review 利用生物合成超顺磁性氧化铁纳米粒子治疗口腔癌的绿色牙科:系统综述
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-11 DOI: 10.2147/cmar.s477791
Faris Hernando Reviansyah, Daffa Rahmad Dwiyana Putra, Juan Alexander Supriatna, Veni Takarini, Maria Komariah
Abstract: Oral cancer is a worldwide health issue with high incidence and mortality, demands an effective treatment to improve patient prognosis. Superparamagnetic iron oxide nanoparticles (SPIONs) emerged as a candidate for oral cancer treatment due to their unique attributes, enabling a synergistic combination with its drug-delivery capabilities and hyperthermia when exposed to magnetic fields. SPIONs can be synthesized using biopolymers from agricultural waste like lignin from paddy, which produce biogenic nano iron oxide with superparamagnetic and antioxidant effects. In addition, lignin also acts as a stabilizing agent in creating SPIONs. This study aimed to explore how agricultural waste could be used to prepare SPIONs using the green synthesis method and to evaluate its potential for oral cancer specifically focusing on its effectiveness, side effects, biocompatibility, and toxicity. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. PubMed, EBSCO, and Scopus databases were exploited in the selection of articles published within the last decade. This study quality assessment uses OHAT for critical appraisal tools. Only 10 studies met the inclusion criteria. The findings suggest that the use of agricultural waste in the preparation of SPIONs not only holds potency for oral cancer treatment through drug delivery and hyperthermia but also aligns with the concept of green dentistry. SPIONs as a treatment modality for oral cancer have demonstrated notable effectiveness and versatility. This study provides robust evidence supporting green dentistry by using agricultural waste in the preparation and formulation of SPIONs for managing oral cancer. Its multifunctional nature and ability to enhance treatment efficacy while minimizing adverse effects on healthy tissues highlights the potency of SPION-based oral cancer treatments.

Keywords: SPIONs, oral cancer, treatment, biosynthesis, green dentistry
摘要:口腔癌是一个世界性的健康问题,发病率和死亡率都很高,需要一种有效的治疗方法来改善患者的预后。超顺磁性氧化铁纳米粒子(SPIONs)因其独特的属性而成为口腔癌治疗的候选材料,当暴露在磁场中时,SPIONs能与药物输送功能和热疗功能协同作用。SPIONs 可利用农业废弃物(如稻谷中的木质素)中的生物聚合物合成,从而产生具有超顺磁性和抗氧化作用的生物纳米氧化铁。此外,木质素还可作为稳定剂生成 SPIONs。本研究旨在探讨如何利用农业废弃物采用绿色合成法制备 SPIONs,并评估其治疗口腔癌的潜力,特别关注其有效性、副作用、生物相容性和毒性。我们按照《系统综述和元分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-Analyses)协议进行了系统综述。在选择过去十年内发表的文章时,使用了 PubMed、EBSCO 和 Scopus 数据库。本研究质量评估使用 OHAT 作为关键评估工具。只有 10 项研究符合纳入标准。研究结果表明,利用农业废弃物制备 SPIONs 不仅可以通过药物输送和热疗治疗口腔癌,而且符合绿色牙科的概念。SPIONs作为一种治疗口腔癌的方法,已显示出显著的有效性和多功能性。本研究通过利用农业废弃物制备和配制 SPIONs 来治疗口腔癌,为绿色牙科提供了有力的证据支持。SPIONs的多功能性以及在提高治疗效果的同时减少对健康组织的不良影响的能力,凸显了基于SPIONs的口腔癌治疗方法的潜力:SPIONs、口腔癌、治疗、生物合成、绿色牙科
{"title":"Green Dentistry in Oral Cancer Treatment Using Biosynthesis Superparamagnetic Iron Oxide Nanoparticles: A Systematic Review","authors":"Faris Hernando Reviansyah, Daffa Rahmad Dwiyana Putra, Juan Alexander Supriatna, Veni Takarini, Maria Komariah","doi":"10.2147/cmar.s477791","DOIUrl":"https://doi.org/10.2147/cmar.s477791","url":null,"abstract":"<strong>Abstract:</strong> Oral cancer is a worldwide health issue with high incidence and mortality, demands an effective treatment to improve patient prognosis. Superparamagnetic iron oxide nanoparticles (SPIONs) emerged as a candidate for oral cancer treatment due to their unique attributes, enabling a synergistic combination with its drug-delivery capabilities and hyperthermia when exposed to magnetic fields. SPIONs can be synthesized using biopolymers from agricultural waste like lignin from paddy, which produce biogenic nano iron oxide with superparamagnetic and antioxidant effects. In addition, lignin also acts as a stabilizing agent in creating SPIONs. This study aimed to explore how agricultural waste could be used to prepare SPIONs using the green synthesis method and to evaluate its potential for oral cancer specifically focusing on its effectiveness, side effects, biocompatibility, and toxicity. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol. PubMed, EBSCO, and Scopus databases were exploited in the selection of articles published within the last decade. This study quality assessment uses OHAT for critical appraisal tools. Only 10 studies met the inclusion criteria. The findings suggest that the use of agricultural waste in the preparation of SPIONs not only holds potency for oral cancer treatment through drug delivery and hyperthermia but also aligns with the concept of green dentistry. SPIONs as a treatment modality for oral cancer have demonstrated notable effectiveness and versatility. This study provides robust evidence supporting green dentistry by using agricultural waste in the preparation and formulation of SPIONs for managing oral cancer. Its multifunctional nature and ability to enhance treatment efficacy while minimizing adverse effects on healthy tissues highlights the potency of SPION-based oral cancer treatments.<br/><br/><strong>Keywords:</strong> SPIONs, oral cancer, treatment, biosynthesis, green dentistry<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"55 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients 化疗对肺癌患者循环淋巴细胞亚群的影响
IF 3.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-09-10 DOI: 10.2147/cmar.s475967
Wei Hong, Lei Zhang, Youkun Qi, Yanjun Wang, Wentao Wang
Purpose: Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as a fundamental component in therapy. Chemotherapy-induced myelosuppression encompasses a spectrum of hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels and platelets. This retrospective cohort study investigates alterations in peripheral blood lymphocyte subsets. By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits of chemotherapy are maximized while minimizing its detrimental effects.
Patients and Methods: We retrospectively analyzed 159 lung cancer patients. Patients were categorized as “NT” (n=108, no previous anti-tumor therapy), and “PT” (n=51, prior therapy followed by at least a two-month treatment-free interval). Post-chemotherapy, patients were reassessed and grouped into “EarlyCycle” for those who underwent four or fewer cycles, and “LateCycle” for those who underwent more than four cycles.
Results: The study focused on analyzing the percentages of lymphocyte subsets, including T cells (CD4+, CD8+), B cells, and natural killer (NK) cells, across these groups. For T cells, the EarlyCycle group exhibited a significant increase compared to NT (0.7783 vs 0.7271; p=0.0017) and PT (0.7783 vs 0.6804; p=1.6e-05). B cells showed a significant decrease from NT to LateCycle (0.1014 vs 0.0817; p=2.2e-05) and from PT to LateCycle (0.1317 vs 0.0817; p=6.2e-10). NK cells significantly decreased in the EarlyCycle group compared to NT (0.1109 vs 0.1462; p=0.00816) and PT (0.1109 vs 0.1513; p=0.00992), with no significant change in the LateCycle group compared to either NT or PT (p> 0.05).
Conclusion: Chemotherapy significantly affects lymphocyte subsets in a treatment-specific manner. The EarlyCycle group experienced a reduction in NK cell and an increase in T cell, suggesting a damage of innate immunity and an early shift towards adaptive immunity. The LateCycle group showed a substantial decrease in B cell, indicating a delayed effect on humoral immunity components.

Keywords: chemotherapy, lung cancer, myelosuppression, peripheral blood, lymphocyte subsets
目的:肺癌仍然是癌症相关死亡的主要原因,而化疗是治疗的基本组成部分。化疗引起的骨髓抑制包括一系列血液学指标的下降,不仅包括中性粒细胞,还包括淋巴细胞、血红蛋白水平和血小板。这项回顾性队列研究调查了外周血淋巴细胞亚群的变化。通过揭示这些变化,我们的目标是完善患者管理策略,确保最大限度地发挥化疗的益处,同时最大限度地减少化疗的不利影响:我们对 159 名肺癌患者进行了回顾性分析。患者被分为 "NT"(人数=108,既往未接受过抗肿瘤治疗)和 "PT"(人数=51,既往接受过治疗后至少有两个月的无治疗间隔期)两类。化疗后,对患者进行重新评估,并将接受四个或四个以下周期治疗的患者分为 "早期周期 "和 "晚期周期":研究重点是分析各组淋巴细胞亚群的百分比,包括 T 细胞(CD4+、CD8+)、B 细胞和自然杀伤细胞(NK)。就 T 细胞而言,EarlyCycle 组比 NT 组(0.7783 vs 0.7271; p=0.0017)和 PT 组(0.7783 vs 0.6804; p=1.6e-05)显著增加。B细胞从NT到LateCycle(0.1014 vs 0.0817;p=2.2e-05)和从PT到LateCycle(0.1317 vs 0.0817;p=6.2e-10)均有显著下降。与NT(0.1109 vs 0.1462; p=0.00816)和PT(0.1109 vs 0.1513; p=0.00992)相比,早周期组的NK细胞明显减少,晚周期组与NT或PT相比无明显变化(p> 0.05):结论:化疗对淋巴细胞亚群的影响具有治疗特异性。早周期组 NK 细胞减少,T 细胞增加,表明先天性免疫受到破坏,适应性免疫早期转移。晚周期组 B 细胞大幅减少,表明对体液免疫成分的影响延迟。
{"title":"Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients","authors":"Wei Hong, Lei Zhang, Youkun Qi, Yanjun Wang, Wentao Wang","doi":"10.2147/cmar.s475967","DOIUrl":"https://doi.org/10.2147/cmar.s475967","url":null,"abstract":"<strong>Purpose:</strong> Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as a fundamental component in therapy. Chemotherapy-induced myelosuppression encompasses a spectrum of hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels and platelets. This retrospective cohort study investigates alterations in peripheral blood lymphocyte subsets. By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits of chemotherapy are maximized while minimizing its detrimental effects.<br/><strong>Patients and Methods:</strong> We retrospectively analyzed 159 lung cancer patients. Patients were categorized as “NT” (n=108, no previous anti-tumor therapy), and “PT” (n=51, prior therapy followed by at least a two-month treatment-free interval). Post-chemotherapy, patients were reassessed and grouped into “EarlyCycle” for those who underwent four or fewer cycles, and “LateCycle” for those who underwent more than four cycles.<br/><strong>Results:</strong> The study focused on analyzing the percentages of lymphocyte subsets, including T cells (CD4+, CD8+), B cells, and natural killer (NK) cells, across these groups. For T cells, the EarlyCycle group exhibited a significant increase compared to NT (0.7783 vs 0.7271; p=0.0017) and PT (0.7783 vs 0.6804; p=1.6e-05). B cells showed a significant decrease from NT to LateCycle (0.1014 vs 0.0817; p=2.2e-05) and from PT to LateCycle (0.1317 vs 0.0817; p=6.2e-10). NK cells significantly decreased in the EarlyCycle group compared to NT (0.1109 vs 0.1462; p=0.00816) and PT (0.1109 vs 0.1513; p=0.00992), with no significant change in the LateCycle group compared to either NT or PT (p&gt; 0.05).<br/><strong>Conclusion:</strong> Chemotherapy significantly affects lymphocyte subsets in a treatment-specific manner. The EarlyCycle group experienced a reduction in NK cell and an increase in T cell, suggesting a damage of innate immunity and an early shift towards adaptive immunity. The LateCycle group showed a substantial decrease in B cell, indicating a delayed effect on humoral immunity components.<br/><br/><strong>Keywords:</strong> chemotherapy, lung cancer, myelosuppression, peripheral blood, lymphocyte subsets<br/>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"16 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Management and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1